hepatitis

[VBI Vaccines, Inc.] VBI Vaccines, Inc. announced the filing of a New Drug Submission to Health Canada for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

[PLoS One] Activated hepatic stellate cell cell lines were used to evaluate the effects of tenofovir disoproxil fumarate and entecavir. After treatment with each antiviral agent, cell viability, morphology, apoptotic features, autophagy and antifibrosis signaling pathways were examined.

[Journal of Gastrointestinal Cancer] The author discusses molecular mechanisms of gut microbiome–related hepatocarcinogenesis and the impact of dysbiosis on chronic liver disease progression.

[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)] Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).

[Science Advances] Investigators found that triggering receptor expressed on myeloid cells 2 (TREM-2) was induced in T cells in the blood and lungs of patients with COVID-19.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that it has submitted a Biologics License Application to the US FDA for bulevirtide for injection, a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.